125 related articles for article (PubMed ID: 28266027)
1. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review.
Habbema L; Halk AB; Neumann M; Bergman W
Int J Dermatol; 2017 Oct; 56(10):975-980. PubMed ID: 28266027
[TBL] [Abstract][Full Text] [Related]
2. Atypical melanocytic naevi following melanotan injection.
Reid C; Fitzgerald T; Fabre A; Kirby B
Ir Med J; 2013 May; 106(5):148-9. PubMed ID: 23914578
[TBL] [Abstract][Full Text] [Related]
3. alpha-Melanocyte-stimulating hormone-induced eruptive nevi.
Cardones AR; Grichnik JM
Arch Dermatol; 2009 Apr; 145(4):441-4. PubMed ID: 19380666
[TBL] [Abstract][Full Text] [Related]
4. A glimpse into the underground market of melanotan.
Callaghan Iii DJ
Dermatol Online J; 2018 May; 24(5):. PubMed ID: 30142729
[TBL] [Abstract][Full Text] [Related]
5. An in-depth case examination of an exotic dancer's experience of melanotan.
Van Hout MC; Brennan R
Int J Drug Policy; 2014 May; 25(3):444-50. PubMed ID: 24280586
[TBL] [Abstract][Full Text] [Related]
6. [Melanotan-induced lentigines and nevi].
Thestrup-Pedersen K; Søndergaard K
Ugeskr Laeger; 2011 Mar; 173(13):975. PubMed ID: 21453640
[TBL] [Abstract][Full Text] [Related]
7. Melanotropic peptides: more than just 'Barbie drugs' and 'sun-tan jabs'?
Langan EA; Nie Z; Rhodes LE
Br J Dermatol; 2010 Sep; 163(3):451-5. PubMed ID: 20545686
[TBL] [Abstract][Full Text] [Related]
8. Melanoma associated with the use of melanotan-II.
Hjuler KF; Lorentzen HF
Dermatology; 2014; 228(1):34-6. PubMed ID: 24355990
[TBL] [Abstract][Full Text] [Related]
9. Melanotan-associated melanoma in situ.
Ong S; Bowling J
Australas J Dermatol; 2012 Nov; 53(4):301-2. PubMed ID: 22724573
[TBL] [Abstract][Full Text] [Related]
10. Change in moles linked to use of unlicensed "sun tan jab".
Langan EA; Ramlogan D; Jamieson LA; Rhodes LE
BMJ; 2009 Jan; 338():b277. PubMed ID: 19174439
[No Abstract] [Full Text] [Related]
11. Use of melanotan I and II in the general population.
Evans-Brown M; Dawson RT; Chandler M; McVeigh J
BMJ; 2009 Feb; 338():b566. PubMed ID: 19224885
[No Abstract] [Full Text] [Related]
12. Eruptive naevi and darkening of pre-existing naevi 24 h after a single mono-dose injection of melanotan II.
Schulze F; Erdmann H; Hardkop LH; Anemüller W; Rose C; Zillikens D; Fischer TW
Eur J Dermatol; 2014; 24(1):107-9. PubMed ID: 24334249
[No Abstract] [Full Text] [Related]
13. Melanotan and the posterior reversible encephalopathy syndrome.
Kaski D; Stafford N; Mehta A; Jenkins IH; Malhotra P
Ann Intern Med; 2013 May; 158(9):707-8. PubMed ID: 23648958
[No Abstract] [Full Text] [Related]
14. A review and update on melanocyte stimulating hormone therapy: afamelanotide.
Fabrikant J; Touloei K; Brown SM
J Drugs Dermatol; 2013 Jul; 12(7):775-9. PubMed ID: 23884489
[TBL] [Abstract][Full Text] [Related]
15. Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications.
Wu J; Cotliar R
J Drugs Dermatol; 2021 Mar; 20(3):290-294. PubMed ID: 33683075
[TBL] [Abstract][Full Text] [Related]
16. [Eruptive dysplastic nevi following melanotan use].
Hueso-Gabriel L; Mahiques Santos L; Terrádez Mas L; Santonja López N
Actas Dermosifiliogr; 2012 May; 103(4):329-31. PubMed ID: 22425244
[No Abstract] [Full Text] [Related]
17. Hemodynamic actions and mechanisms of systemically administered α-MSH analogs in mice.
Rinne P; Tikka S; Mäkelä S; Streng T; Savontaus E
Peptides; 2012 Nov; 38(1):150-8. PubMed ID: 22982611
[TBL] [Abstract][Full Text] [Related]
18. [Eruptive nevi after injection of drugs marketed as melanotan II. The first two Swedish cases described].
Burian E; Burian E
Lakartidningen; 2013 Jan 30-Feb 5; 110(5):208-10. PubMed ID: 23451671
[No Abstract] [Full Text] [Related]
19. Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders.
Minder EI; Barman-Aksoezen J; Schneider-Yin X
Clin Pharmacokinet; 2017 Aug; 56(8):815-823. PubMed ID: 28063031
[TBL] [Abstract][Full Text] [Related]
20. A bioassay for the detection of neutralizing antibodies against the α-melanocyte stimulating hormone analog afamelanotide in patients with erythropoietic protoporphyria.
Spichty R; Balimann M; Barman J; Minder EI
J Pharm Biomed Anal; 2013 Mar; 75():192-8. PubMed ID: 23277150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
